QR Code

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

Description complète

Enregistré dans:
Auteurs principaux: Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021-11-01
Collection:JTO Clinical and Research Reports
Sujets:
Lung cancer
MET
Nivolumab
Amplification
Immune checkpoint inhibitor
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S2666364321000989
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires